InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,269.12
(
-0.16%
)
US TECH 100
18,090.40
(
0.34%
)
Dow Jones
38,413.56
(
-0.71%
)
Brent Oil
78.45
(
-2.92%
)
Bitcoin
69,219.99
(
2.17%
)
Post# of 417
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

joe_techi

Send PM Follow Ignore
Followers 32
Posts 3270
Boards Moderated 0
Alias Born 08/31/2006

joe_techi

Re: None

Wednesday, 11/19/2014 10:30:29 AM

Wednesday, November 19, 2014 10:30:29 AM

Post# of 417
Nuvilex Announces Preliminary Data From Preclinical Study of Effects of Its Pancreatic Cancer Treatment on Ascites Fluid Formation

"Preliminary data analysis suggests that treatment with Nuvilex's live-cell encapsulation technology, Cell-in-a-Box® plus ifosfamide, produces a significant survival advantage as compared to non-treated control animals. Nuvilex's treatment appears to be at least as good as cisplatin, the current standard of care for ovarian cancer. However, when the encapsulated cells plus ifosfamide were used in conjunction with cisplatin, the survival rate was greatly enhanced."


http://www.nasdaq.com/press-release/nuvilex-announces-preliminary-data-from-preclinical-study-of-effects-of-its-pancreatic-cancer-20141119-00614
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up